Effect of immunodeficiency and tumor marker expression on HIV-related diffuse large B-cell lymphoma prognosis
© Silverberg et al; licensee BioMed Central Ltd. 2012
Published: 19 April 2012
Several tumor markers may predict survival in HIV+ patients with diffuse large B-cell lymphoma (DLBCL). Here, we evaluate the association of immunodeficiency (CD4<200) on expression of prognostic tumor markers and survival.
HIV+ DLBCL cases diagnosed between 1996-2007 within Kaiser Permanente California were identified. H&E slides were reviewed to identify representative tumor blocks for tissue microarray (TMA) construction. Immunohistochemistry staining of TMA cores was used to detect the expression of selected markers in the categories of (1) cell cycle regulators, (2) B-cell activators, (3) anti-apoptotic proteins, and (4) others, including Epstein Barr Virus (EBV). Percent of DLBCL cells with visible marker staining was scored on a scale from 0-4 (i.e., 0-9%, 10-24%, 25-49%, 50-74% and ≥75%). EBV infection was determined by in situ hybridization of EBV RNA. We also considered high vs. low expression levels based on previously established cut-offs. Of the 20 markers previously examined, three had emerged as significant predictors of survival, including EBV, cMYC and BLIMP1. Here, we evaluated the association between CD4 and expression of these three markers by t-test for mean levels and chi-square for % high levels. We also evaluated the combined effect of immunodeficiency and marker expression on 2-year survival in unadjusted Cox models.
Tumor marker levels by CD4
% high levels
Two-year survival by CD4 and marker levels
Low CD4/high marker
Low CD4/low marker
High CD4/high marker
High CD4/low marker (ref)
Immunodeficiency was associated with EBV+ DLBCL. Cases with low CD4 and high levels of EBV or cMYC had worse survival. Risk stratification may consider both CD4 and tumor marker expression, although confirmation is needed in larger studies.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.